Targeting Prostate Cancer, The 'Tousled Way' v2

Androgen deprivation therapy (ADT) has been the mainstay of prostate cancer (PCa) treatment, with success in developing more effective inhibitors of androgen synthesis and antiandrogens in clinical practice. However, hormone deprivation and AR ablation have caused an increase in ADT-insensitive PCas' associated with poor prognosis. Resistance to ADT arises through various mechanisms, and ...

Androgen deprivation therapy (ADT) has been the mainstay of prostate cancer (PCa) treatment, with success in developing more effective inhibitors of androgen synthesis and antiandrogens in clinical practice. However, hormone deprivation and AR ablation have caused an increase in ADT-insensitive PCas associated with a poor prognosis. Resistance to ADT arises through various mechanisms, and most ...
Targeting Prostate Cancer, the 'Tousled Way'

Androgen deprivation therapy (ADT) has been the mainstay of prostate cancer (PCa) treatment, with success in developing more effective inhibitors of androgen synthesis and antiandrogens in clinical practice. However, hormone deprivation and AR ablation have caused an increase in ADT-insensitive PCas …
Abstract Androgen deprivation therapy (ADT) has been the mainstay of prostate cancer (PCa) treatment, with success in developing more effective inhibitors of androgen synthesis and antiandrogens in clinical practice. However, hormone deprivation and AR ablation have caused an increase in ADT-insensitive PCas associated with a poor prognosis.

PDF Targeting Prostate Cancer, the Tousled Way
Abstract:Androgen deprivation therapy (ADT) has been the mainstay of prostate cancer (PCa) treat- ment, with success in developing more effective inhibitors of androgen synthesis and antiandrogens in clinical practice. However, hormone deprivation and AR ablation have caused an increase in ADT-insensitive PCas associated with a poor prognosis.
Abstract: Androgen deprivation therapy (ADT) has been the mainstay of prostate cancer (PCa) treatment, with success in developing more effective inhibitors of androgen synthesis and anti-androgens ...

Targeting Prostate Cancer, the 'Tousled Way'
Targeting TLK1 and its associated signaling could prevent PCa progression to the incurable metastatic castration-resistant PCa (mCRPC) stage and provide a promising approach to treating PCa. Androgen deprivation therapy (ADT) has been the mainstay of prostate cancer (PCa) treatment, with success in developing more effective inhibitors of androgen synthesis and antiandrogens in clinical ...
Review Targeting Prostate Cancer,The ' Tousled Way ' Siddhant Bhoir and Arrigo De Benedetti Department of Biochemistry and Molecular Biology, LSU Health Shreveport, LA 71103, USA C o ...

Targeting Prostate Cancer, the 'Tousled Way'.
Abstract Androgen deprivation therapy (ADT) has been the mainstay of prostate cancer (PCa) treatment, with success in developing more effective inhibitors of androgen synthesis and antiandrogens in clinical practice. However, hormone deprivation and AR ablation have caused an increase in ADT-insensitive PCas associated with a poor prognosis.









Bhoir S, De Benedetti A. Targeting Prostate Cancer , the 'Tousled Way' . International Journal of Molecular Sciences. 2023; 24 (13):11100. https://doi.org/10.3390/ijms241311100